Platelet and Plasma Market 2020 By Revenue, Top Trend & Regional Growth Forecast

Platelet and Plasma Market report offers in-depth analysis of the industry size, share, major segments, and different geographic regions, forecast for the next five years, key market players, and premium industry trends. It also focuses on the key drivers, restraints, opportunities and industry challenges.

Increasing use of plasma and platelets for treatment of rare diseases like hereditary angioedema, alpha-1 antitrypsin deficiency, hemophilia and others is poised to drive their global consumption outlook. Growing prevalence of liver diseases among the elderly population along with rising cases of liver cirrhosis, non-alcoholic steatohepatitis, pediatric liver disease, liver cancer, hepatocellular carcinoma and alcohol-related liver disease among others has fueled the demand for platelet and plasma for disease treatment.

As per the American Liver Foundation estimates, around 8,000 women and 21,000 men are affected by liver cancer annually in the U.S. Favorable government initiatives to encourage blood donation among individuals may favor industry growth. Advancement in therapeutic protein drug treatment along with rise in demand for advanced therapies for treatment of several rare diseases will boost product demand in the coming years.

Request for a sample copy of this report @

Reports suggest that global platelet and plasma market size will exceed USD 7.1 Billion in terms of annual remunerations by 2026. Rise in in number of hemorrhage cases, especially postpartum is contributing to heavy demand for platelets and plasma. Hemorrhage refers to abnormal blood loss from inside of the body, while, PPH (Postpartum hemorrhage) refers to a heavy loss of blood post-pregnancy.

According to the WHO estimates, postpartum hemorrhage is one of the major causes of maternal mortality in low-income countries. From hemorrhage application, platelet and plasma market will gain revenues at a steady CAGR over 2020-2026.

In 2019, plasma segment held 33% of the platelet and plasma market share worldwide as it is used for the treatment of various diseases. It is widely used to treat individuals suffering from a shock, burn, multiple clotting factor deficiencies, liver disease and others. Growing prevalence of chronic and neurological diseases resulting in increased demand for plasma for treatment will favor business growth.

Hospitals segment in 2019 accounted for 62% of the overall market share. The rise in number of hospital visits for the treatment of chronic diseases and other health-related issues will supplement industry share. Patients prefer treatment of cancer, diabetes, epilepsy, heart disease and other chronic diseases in hospitals due to availability of blood transfusions. In addition, availability of advanced healthcare facilities and technologies with favorable reimbursement policies for hospital treatment will foster the market size.

Request for customization @

APAC platelet and plasma market was valued at over USD 1.7 Billion in 2019 and is estimated to gain traction through 2026 on account of the consistent development of healthcare infrastructure in the region. In addition, favorable initiatives by several organizations such to create awareness for blood donation will foster regional growth.

Key business players operating in the global platelet and plasma industry include American Association of Blood Banks, America’s Blood Centers, American Red Cross, Indian Red Cross, European Blood Alliance, Blood Centers of America, South African Red Cross Society, Japanese Red Cross, OneBlood and Italian Red Cross. Partnerships are a key part in ensuring consistent service is available to patients in need across territories. 

Partial Chapter of the Table of Content 

Chapter 2.  Executive Summary

2.1. Platelet and plasma industry 3600 synopsis, 2015 – 2026

2.1.1.  Business trends

2.1.2.  Component trends

2.1.3.  Application trends

2.1.4.  Distribution channel trends

2.1.5.  Regional trends

Chapter 3.  Platelet and Plasma Industry Insights

3.1. Industry segmentation

3.2. Industry landscape, 2015 – 2026

3.3. Industry ecosystem

3.3.1.  Value chain analysis

3.3.2.  Distribution channel analysis

3.4. Industry impact forces

3.4.1.  Growth drivers Higher number of blood transfusions in Europe Recent advances in therapeutic protein drug development Increasing prevalence of liver diseases in elderly population Exclusive use of plasma for treatment of rare diseases in Europe Fair reimbursement in developed countries

3.4.2.  Industry pitfalls & challenges Stringent regulatory policies Affordability issue in APAC and Latin America due to high costs

3.5. Growth potential analysis

3.5.1.  By component

3.5.2.  By application

3.5.3.  By distribution channel

3.6. COVID-19 impact analysis

3.7. Porter’s analysis

3.8. PESTEL analysis 

Browse full table of contents (TOC) of this report @